Researcher.Life Logo

Urologic Oncology: Seminars and Original Investigations : Impact Factor & More

eISSN: 1873-2496pISSN: 1078-1439

Key Metrics

CiteScore
4.7
H-Index
79
Impact Factor
< 5
SJR
Q1Urology
SNIP
1.01
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Urologic Oncology: Seminars and Original Investigations

Urologic Oncology: Seminars and Original Investigations Journal Specifications

Overview
Publisher ELSEVIER SCIENCE INC
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year2003
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Urologic Oncology: Seminars and Original Investigations ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Urologic Oncology: Seminars and Original Investigations

Evaluating BCG response in primary and metachronous non-muscle invasive bladder cancer following prior upper tract urothelial cancer: A systematic review and meta-analysis.
  • 1 Jun 2026
  • Urologic oncology
Outcomes of consolidative surgery following enfortumab vedotin plus pembrolizumab for advanced urothelial cancer: A real-world experience.
  • 1 Jun 2026
  • Urologic oncology
Adequate Bacillus Calmette-Guérin maintenance therapy improves recurrence-free survival in high-risk non-muscle-invasive bladder cancer: A conditional survival study.
  • 1 Jun 2026
  • Urologic oncology
Postchemotherapy orchiectomy in metastatic testicular germ cell tumors: Pathologic findings and predictors of residual viable disease.
  • 1 Jun 2026
  • Urologic oncology
Clinical trial participation in kidney, bladder, and prostate malignancies in the United States: Sociodemographic distribution and impact on survival.
  • 1 Jun 2026
  • Urologic oncology
Casein kinase 1α inhibition reduces prostate cancer cells viability: Role of the autophagy mechanism.
  • 1 Jun 2026
  • Urologic oncology
Evaluating BCG response in primary and metachronous non-muscle invasive bladder cancer following prior upper tract urothelial cancer: A systematic review and meta-analysis.
  • 1 Jun 2026
  • Urologic oncology
Outcomes of consolidative surgery following enfortumab vedotin plus pembrolizumab for advanced urothelial cancer: A real-world experience.
  • 1 Jun 2026
  • Urologic oncology
Adequate Bacillus Calmette-Guérin maintenance therapy improves recurrence-free survival in high-risk non-muscle-invasive bladder cancer: A conditional survival study.
  • 1 Jun 2026
  • Urologic oncology
Postchemotherapy orchiectomy in metastatic testicular germ cell tumors: Pathologic findings and predictors of residual viable disease.
  • 1 Jun 2026
  • Urologic oncology
Clinical trial participation in kidney, bladder, and prostate malignancies in the United States: Sociodemographic distribution and impact on survival.
  • 1 Jun 2026
  • Urologic oncology
Casein kinase 1α inhibition reduces prostate cancer cells viability: Role of the autophagy mechanism.
  • 1 Jun 2026
  • Urologic oncology

FAQs on Urologic Oncology: Seminars and Original Investigations